Search

Dedicated care of Skin of Color (SOC) individuals is crucial for increasing access and culturally-sensitive management of this population [1]. Although SOC specialty clinics (SOCSC) are becoming increasingly popular, data on these is limited. We seek to describe the first detailed experience from a SOCSC. Demographic and clinical data of the University of Nebraska Medical Center Department of Dermatology's Ethnic Skin/SOC Clinic were collected. Of 252 patients, 82% were female; mean age was 45.1 years. Self-reported race consisted of Black/African-Americans (86.9%), Other (6.0%), and Asians (3.6%). Hispanics/Latinos constituted 4.8%. The top chief complaints (CC) included acne, itch/rash, and hair loss. Among patients previously seen by a dermatologist, 20.3% had a diagnosis change, 24.3% received a new diagnosis unrelated to CC, and 48.6% had a treatment change. Patients with a prior dermatology visit showed a higher rate of change in diagnosis (20.3% vs. 2.8%) and change in treatment (48.6% vs. 28.0%) than those without. The most common diagnosis changes were itch/rash (29.3%) and hair loss (19%). Changes in treatment were mostly seen in patients with acne (20.8%), and the most common were discontinuation (50%) and switch in antibiotics (11%). In patients with previous dermatologic contact, one out of five patients (20.3%) previously seen by a non-SOC dermatologist had a diagnosis change, one out of four (24.3%) had a new diagnosis, half (48.6%) had a change in treatment, and 17.6% were being diagnosed and treated for the first time after being seen in SOCSC, highlighting the importance of SOC-specialized dermatologists in patient care., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

The use of medications which target the JAK-STAT signaling pathway, also known as janus kinase (JAK) inhibitors, has rapidly increased in recent years. Patient perceptions, opinions, and concerns regarding the use of JAK inhibitors are largely uninvestigated. Our objective is to better understand patient concerns, reported side effects, and sentiments regarding the use of JAK inhibitors for dermatologic disease. The authors performed a cross-sectional analysis of the most frequented subreddits for dermatologic disease in which JAK inhibitors have obtained FDA approval (r/atopic dermatitis, r/psoriasis, r/alopecia areata, r/vitiligo, and r/eczeJAKS). The sentiment, central theme, and engagement level of each post was evaluated using previously utilized methods. Nine hundred twenty-three posts were analyzed, with the majority focusing on efficacy (433, 47%) and medication-related side effects (150, 16%). Other themes of interest to patients were Payment/Insurance (84, 9%), Study Results/News (69, 7%), Administration/Dosage (33, 4%), and Medication Interactions (31, 3%). The most frequently reported side effects were acne/folliculitis (24, 22%), nausea/gastrointestinal disturbance (11,10%), and fatigue/muscle aches (10, 9%). At the same time, the medication interactions garnering the most concern were sunscreens/facial moisturizers (5, 16%), topical calcineurin inhibitors (4, 13%), and Marijuana/THC (3, 9.%). This analysis highlights that patients are most concerned about the efficacy and side effects of JAK inhibitors in addition to issues regarding access to JAK inhibitors. Providers can use the insights gained from this study to address hesitancy better and guide comprehensive, patient-centered discussions with patients regarding JAK inhibitor use., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)